MedTrace Logo

Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome

NCT02037412 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2019-03-29

No results posted yet for this study

Summary

The investigators hypothesized that ticagrelor may enhance endothelial healing after DES implantation by increasing adenosine concentrations by the inhibition of adenosine uptake into erythrocytes, compared to clopidogrel. Thus, the investigators will evaluate the extent of endothelialization (stent strut coverage) and neointimal hyperplasia (neointimal thickness) 3 months after DES implantation by optical coherence tomography (OCT)

Conditions

  • Acute Coronary Syndrome
  • Acute Myocardial Infarction
  • Unstable Angina (Intermediate Coronary Syndrome)

Interventions

DRUG

Ticagrelor

Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months

DRUG

Clopidogrel

Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02037412 on ClinicalTrials.gov